GlaxoSmithKline PLC (GSK) Shares Bought by Integrated Wealth Counsel LLC

Cornelia Mascio
Settembre 13, 2017

4,349,903 shares of the company were exchanged. GlaxoSmithKline PLC makes up about 1.1% of PARK CIRCLE Co's holdings, making the stock its 25th biggest holding. Integrated Wealth Counsel LLC's holdings in GlaxoSmithKline PLC were worth $181,000 as of its most recent filing with the SEC.

Other equities research analysts have also issued research reports about the stock. Fisher Asset Management LLC raised its position in shares of GlaxoSmithKline PLC by 4.7% in the second quarter. Astenbeck Capital Management Llc owns 150,545 shares or 19.39% of their U.S. portfolio. Finally, BlueCrest Capital Management Ltd lifted its stake in GlaxoSmithKline PLC by 293.5% in the 1st quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company's stock worth $827,000 after purchasing an additional 57 shares in the last quarter. 10 15 Associates Inc. lifted its stake in GlaxoSmithKline PLC by 6.4% in the 1st quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company's stock worth $2,157,000 after purchasing an additional 38,157 shares in the last quarter. Kanawha Capital Management Ltd Llc holds 174,255 shares. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company's stock worth $137,000 after purchasing an additional 64 shares in the last quarter.

Among 28 analysts covering GlaxoSmithKline PLC (LON:GSK), 9 have Buy rating, 4 Sell and 15 Hold.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business.

GlaxoSmithKline plc (LON:GSK) opened at 1496.50 on Wednesday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.53. The firm has a 50-day moving average of $39.94 and a 200 day moving average of $41.81. The company has market cap of $96.78 billion. Bank of America upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Tuesday, September 8 to "Neutral" rating. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%.

The business also recently announced a dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 annualized dividend and a dividend yield of 4.86%. This is a positive change from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. GlaxoSmithKline PLC's dividend payout ratio (DPR) is now 197.00%.

10/25/2016 - GlaxoSmithKline PLC had its "buy" rating reiterated by analysts at Beaufort Securities. If you are reading this story on another publication, it was illegally stolen and reposted in violation of US and worldwide trademark & copyright law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/morgan-stanley-lowers-glaxosmithkline-plc-gsk-to-underweight/1623460.html.

A number of brokerages have issued reports on GSK. The stock has "Neutral" rating by BNP Paribas on Tuesday, September 15. The stock of GlaxoSmithKline plc (LON:GSK) has "Hold" rating given on Thursday, September 10 by Jefferies. Finally, Barclays PLC reaffirmed an "equal weight" rating and set a GBX 1,550 ($20.02) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 27th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company's stock. The price target means a potential upside of 5.55% from firm's current price.

The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Buy" rating given on Wednesday, January 27 by Bryan Garnier & Cie. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE